# Sublingual Atropine Bioequivalence by Route of Administration (SABER)

> **NCT06366087** · PHASE1 · COMPLETED · sponsor: **Biomedical Advanced Research and Development Authority** · enrollment: 46 (actual)

## Conditions studied

- Atropine Bioequivalence

## Interventions

- **DRUG:** Atropine Sulfate Ophthalmic Solution USP, 1%
- **DRUG:** Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)

## Key facts

- **NCT ID:** NCT06366087
- **Lead sponsor:** Biomedical Advanced Research and Development Authority
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-15
- **Primary completion:** 2024-05-15
- **Final completion:** 2024-05-22
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2026-01-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06366087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06366087, "Sublingual Atropine Bioequivalence by Route of Administration (SABER)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06366087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*